Bruna Corradetti, PhD, MSc

Bruna Corradetti received a Ph.D. in Biomolecular Science from Polytechnic University of Marche (Italy) in 2012 working on the development of stem cell-based therapeutic approaches for the treatment of spontaneous tendon injuries. In 2013 she was appointed as Assistant Professor in Genetics in the same university and joined the Houston Methodist Research Institute in the context of a Fellowship for Molecular Medicine. There, Dr. Corradetti expanded her research to material science and nanotechnology and to their applications in the fields of tissue engineering, regenerative medicine, and immunomodulation. She conceived and developed naturally inspired platforms and delivery systems able to support tissue regeneration by modulating stem and immune cells behavior. Since 2015 Dr. Corradetti has served as Associate Member for the Houston Methodist Research Institute and in 2016 as Visiting Professor at the Department of Mechanics and Materials at ETH Zurich working with Prof. Chiara Daraio.

In 2016 Dr. Corradetti was nominated Fellow of the Academy of Translational Medicine Professionals and since then she serves as Secretary of the European Society for Translational Medicine. In 2017 Dr. Corradetti has been recognized among the “100 Italian Excellences.” Dr. Corradetti has published more than 40 peer-reviewed papers and served as the sole Editor of the book entitled “The Immune Response to Implanted Materials and Devices. The Impact of the Immune System on the Success of an Implant” published by Springer International in 2017.

In 2018 Dr. Corradetti has joined the Houston Methodist Research Institute as Assistant Research Professor and was appointed as Associate Professor in the School of Medicine at Swansea University (Wales, UK). Her work is partially supported through the Sêr Cymru II program, funded by the European Commission through the Horizon 2020 Marie Skłodowska-Curie Actions (MSCA) COFUND scheme and the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF).

- Natural and bio-inspired artificial platforms for the delivery of RNA therapeutics.

- Biomimetic strategies to improve tissue regeneration and modulate the immune response.

- Synthetic biomimetic extracellular matrices for the healing of chronic wounds and cell transplantation.

- Development of exosome-based vaccines to induce anti-cancer immune response.